Thau, L., Gandhi, J., & Sharma, S
2.6 Dihydroflavonol 2.6.1 SL About 50%70% of the silymarin extract consists of the flavonolignan SL, which is extensively studied and regarded as the most active component of silymarin (Loguercio and Festi, 2011)
Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number
These doses are initiated after careful dosage titration to minimize side effects
There is no clinical study data available to support the products claims